Document:

Letter Agreement - W. Thomas Amick

 Exhibit 10.15 
 BIOLEX 
 W. Thomas Amick 
 5419 Ocean Drive, 
 Emerald Isle, NC 28594 
 Dear Tom: 
 This will confirm our discussion relating to your becoming a member of the Board of Directors of Biolex, Inc.
(“Biolex”). We are very excited that you are joining our Board and look forward to building a truly transformational company with your assistance. 
 As we discussed, you have agreed to serve on Biolex’ Board as an Independent Director, as the designee of our two principal investors, Intersouth Partners V and Quaker BioVentures, in accordance with Biolex’
August 8, 2003 Second Amended and Restated Investor Rights Agreement. 
 We currently estimate that you would provide the equivalent of
approximately 10 days of service per year, excluding your travel time and meeting preparation time. Your services would include (i) preparing for and participating in quarterly Board meetings, (ii) evaluating Biolex’ business plans
and assessing its opportunities and (iii) otherwise providing Biolex with your expertise as requested from time to time. The Board will meet regularly at least once per quarter and the Directors should otherwise be available informally on an
as-requested basis. In addition, the Directors are expected to be available on short notice for special meetings of the Board and for actions taken by written consent. 
 While you are a Director, Biolex will pay you an annual fee of $10,000, and will also reimburse you for your reasonable and necessary expenses incurred as a result of attending a meeting in person. In addition,
effective upon the commencement of your term as a Director, you will be granted an option pursuant to Biolex’ 2003 Equity Incentive Plan to acquire 20,000 shares of Biolex’ common stock, with such shares vesting over one year in quarterly
increments of 25% (with the initial installment vesting on the 90th day from March 4, 2004, the date of your election to the Board). On the first anniversary of your term as a Director and on each anniversary date thereafter, so long as you
remain a Director, you will be granted an additional option to acquire 10,000 shares of Biolex’ common stock, which will vest immediately when granted. 
 Biolex also carries Directors’ and Officers’ liability insurance covering all members of the Board, in addition to standard statutory rights to indemnification. As a Director, you will be expected to serve
the best interests of the company, consistent with applicable law. Please let us know if you would like our legal counsel to review directors’ legal duties and responsibilities with you. 
 This letter constitutes a non-binding agreement, creating no rights or obligations on the part of either you or Biolex and is intended only to set forth
the essential terms of our discussions. 

			
	158 Credle Street	 	tel 919.542.9901
	Pittsboro, NC 27312	 	fax 919.542.9910
	www.biolex.com	 	

 If these understandings are correct, please countersign where indicated below. 
  

			
	Sincerely,
	
	BIOLEX, INC.
		
	 By:
	 	 /s/ W. Chris Hegele

	 Name:
	 	W. Chris Hegele
	 Title:
	 	Chairman of the Board
		
	 By:
	 	 /s/ Jan Turek

	 Name:
	 	Jan Turek
	 Title:
	 	President and CEO

  

			
	ACKNOWLEDGED AND AGREED:	 	
		
	 /s/ W. Thomas Amick
	 	
	W. Thomas Amick	 	

  

 2Letter Agreement - David Castaldi

 Exhibit 10.16 
 [BIOLEX LETTERHEAD] 
 David Castaldi 
 11 Bellingham Road 
 Chestnut Hill, MA 02467-3229 
 May 19, 2004 
 Dear David, 
 This
will confirm our discussion relating to your becoming a member of the Board of Directors of Biolex, Inc. (“Biolex”). We are very excited, that you are joining our Board and look forward to building a truly transformational company with
your assistance. 
 As we discussed, you have agreed to serve on Biolex’ Board as an Independent Director, as the designee of our two
principal Investors, Intersouth Partners V and Quaker BioVentures, in accordance with Biolex’ August 8, 2003 Second Amended and Restated Investor Rights Agreement. 
 We currently estimate that you would provide the equivalent of approximately 10 days of service per year, excluding your travel time and meeting
preparation time. Your services would include (i) preparing for and participating in quarterly Board meetings, (ii) evaluating Biolex’ business plans and assessing its opportunities and (iii) otherwise providing Biolex with your
expertise as requested from time to time. The Board will meet regularly at least once per quarter and the Directors should otherwise be available informally on an as-requested basis. In addition, the Directors, are expected to be available on short
notice for special meetings of the Board and for actions taken by written consent. 
 While you are a Director, Biolex will pay you an annual fee of $10,000, and will also reimburse you for your reasonable and necessary expenses incurred as a result of attending a meeting in person. In addition, effective upon the
commencement of your term as a Director, you will be granted an option pursuant to Biolex’ 2003 Equity Incentive Plan to acquire 20,000 shares of Biolex’ common stock, with such shares vesting over one year in quarterly increments of 25%
(with the initial installment vesting on the 90th day from May 19, 2004, the date of your election to the Board). On the first anniversary of your
term as a Director and on each anniversary date thereafter, so long as you remain a Director, you will be granted an additional option to acquire 10,000 shares of Biolex’ common stock, which will vest immediately when granted.

 Biolex also, carries Directors’ and Officers’ liability insurance covering all members of the Board, in addition to
standard statutory rights to indemnification. As a Director, you will be expected to serve the best interests of the company, consistent with applicable law. Please let us know if you would like our legal counsel to review directors’ legal
duties and responsibilities with you. 
 This letter constitutes a non-binding agreement, creating no rights or obligations on the part of
either you or Biolex and is intended only to set forth the essential terms of our discussions. 

 If these understandings are correct, please countersign where indicated below. 
  

			
	Sincerely,
	
	BIOLEX, INC.
		
	By:	 	 /s/ W. Chris Hegele

	Name:	 	W. Chris Hegele
	Title:	 	Chairman of the Board
		
	By:	 	 /s/ Jan Turek

	Name:	 	Jan Turek
	Title:	 	President and CEO

  

	
	ACKNOWLEDGED AND AGREED:
	
	 /s/ David Castaldi

	David CastaldiLetter agreement dated April 5, 2007

 Exhibit 10.1 
 April 5, 2007 
 Mr. Craig McKibben 
 Dear
Craig: 
 It is my pleasure to set forth your incentive plan for 2007. The following goals recognize that our Board of Directors and I look forward to your
assistance during this period of transition. Your many years with the Company give you a unique understanding into many of the issues which it faces and perspective into how they might be successfully addressed. The following issues have been
identified as your areas of principal focus. 
  

	 	•	 	 Assist the Nominating Committee and Board of Directors in assessing the qualifications of new board candidates, to include developing a framework to facilitate the
interview of prospective candidates and personal references, obtaining Backtrack Reports and documenting the results of such assessments. 

  

	 	•	 	 Assist the CEO in evaluating the financial impacts of alternative debt restructuring plans with the goal of providing the Company with additional time and resources
to pursue plans to monetize its intellectual property and grow Ampex Data Systems in order to enable the Company to satisfy its obligations. 

  

	 	•	 	 Assist the CEO and Vice President of Licensing in developing negotiating strategies with the Court’s Mediation Committee and Kodak management to design a
financial settlement to quickly resolve the Kodak litigation. If unsuccessful, identify alternative financing strategies other than 100% internal funding in order to pursue a trial should the appeal be decided in Ampex’s favor.

  

	 	•	 	 Assist the CEO in evaluating the financial commitments associated with third party proposals to further monetize the Company’s intellectual property and to
devise alternative methods of compensation that reward success. 

 Your target incentive plan for 2007 is $150,000 which shall be earned by
your completion of the above objectives. Incentive compensation for 2007 will be paid no later than January 2008. 
 On behalf of the rest of the Board, I
look forward to working with you to achieve these transitional objectives. 
 Sincerely, 
 Gordon Strickland 
 cc. Peter SlusserOmnibus Amendment to Business Loan Agreement and Warrants

 Exhibit 10.24 
 OMNIBUS AMENDMENT TO BUSINESS LOAN AGREEMENT AND WARRANTS DATED
OCTOBER 3, 
 2003, APRIL 30, 2004, OCTOBER 26, 2004
AND FEBRUARY 10, 2006 
 This Omnibus Amendment (this “Amendment”) to the Business
Loan Agreement, dated as of July 1, 2003 (the “Loan Agreement”), by and between BWCA I, LLC (“BWCA”) and Basin Water, Inc. (“Basin Water”) and the Warrants dated October 3,
2003, April 30, 2004, October 26, 2004 and February 10, 2006 to purchase a total of 767,450 shares of common stock, par value $0.001 per share (“Common Stock”), of Basin Water (the
“Warrants” and together with the Loan Agreement, the “Agreements”) is made as of August 13, 2007, by and between BWCA and Basin Water. Capitalized terms used herein and not otherwise defined shall have the
meanings assigned to them in the Loan Agreement or the Warrants, as applicable. 
 WHEREAS, Basin Water prepaid the Loans outstanding under
the Loan Agreement shortly after Basin Water’s initial public offering; 
 WHEREAS, pursuant to the Section 2k. of the Loan
Agreement, Basin Water must pay a prepayment penalty of 5% with respect to the amount prepaid; 
 WHEREAS, BWCA and Basin Water have agreed
to amend the Loan Agreement to waive a portion of the prepayment penalty and to amend the Warrants so as to make them exercisable on a cashless basis as set forth herein; and 
 WHEREAS, each of the Loan Agreement and the Warrants may be amended upon the written consent of each of BWCA and Basin Water. 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound
hereby, the parties hereto agree as follows: 
 1. Section 2k. of the Loan Agreement is hereby amended such that all references to
“5%” shall be changed to “2.5%.” The parties to this Amendment hereby agree and acknowledge that the prepayment penalty to be paid by Basin Water to BWCA after giving effect to this Amendment is $ 99,350 (the “Payoff
Amount”). 
 2. The Warrants represent all of the warrants to purchase Common Stock owned by BWCA. 
 3. Section 4 of each of the Warrants shall be replaced in its entirety with the following: 
 “4. Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 3 above, the Holder may
exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by: 
 (a) the surrender
of the Warrant to the Secretary of the Company at its principal offices; and 

 (b) either (i) delivery of a duly executed copy of the form of Notice of Exercise
attached hereto electing to pay the Exercise Price in cash, together with payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased, or (ii) delivery of a duly executed copy of the form
of Notice of Exercise attached hereto electing a cashless exercise, pursuant to which the Holder will receive the number of Shares calculated in accordance with the sentence below (a “Cashless Exercise”). 
 In the event the Holder elects a Cashless Exercise, it shall receive a number of Shares computed using the following formula: 
  

											
		  	X	  	=	  	Y (A-B)	 		  	
		  		  		  	A	 		  	

 Where: 
 X = the number of Shares to be issued to the Holder; 
 Y = the number of Shares purchasable under the Warrant, or if only a portion of the Warrant is being exercised, the portion of the Warrant
being exercised (at the date of such calculation); 
 A = the last sale price of the Common Stock on the trading day prior to
the date of exercise of the Warrant or, in case no such reported sales take place on such day, the average of the last reported bid and ask prices of the Common Stock on such day, in either case on the principal national securities exchange on which
the Common Stock is admitted to trading or listed, including the Nasdaq Global Market, or if the Common Stock is not listed or admitted to trading on any such exchange, the high per share bid price for the Common Stock in the over-the-counter market
as reported by The Pink Sheets or similar organization, or if not so available, the fair market value of the Common Stock as determined in good faith by the Company’s Board of Directors; and 
 B = the Exercise Price. 
 4.
The Notice of Exercise of each Warrant shall be replaced in its entirety with the Notice of Exercise attached hereto as Exhibit A. 
 5. Effective immediately upon the payment by Basin Water of the Payoff Amount to BWCA: 
 (a) All provisions of,
rights granted to BWCA under, and obligations, liabilities, covenants and agreements of Basin Water under or in connection with the Loan Agreement, the Commercial Security Agreement, dated as of July 1, 2003, by and between BWCA and Basin Water
(the “Security Agreement”), and each Promissory Note issued under or in connection with the Loan Agreement (the “Notes”) and any Related Documents (as defined in the Loan Agreement, and together with the Loan
Agreement, the Security Agreement and the Notes, the “Loan Documents”) are hereby terminated, released and cancelled in their entirety and are of no further force or effect, and all amounts outstanding under the Loan Documents,
including any Loans, have been paid in full; provided that, notwithstanding anything else to the contrary contained in this Amendment, this Amendment does not act as a waiver or release of any claims against Basin Water under the Warrants held by
BWCA. 
  

 - 2 - 

 (b) BWCA does hereby release and discharge any and all right, title and interest that it
may have or that it may be entitled to by virtue of the Loan Documents, or Security Interest (as defined in the Loan Agreement) granted or recorded in its favor in the Collateral (as defined in the Security Agreement) and does hereby declare the
same fully released and discharged from any and all Security Interests created by the Loan Documents; 
 (c) BWCA does hereby
authorize Basin Water to file Uniform Commercial Code termination statements with respect to any Uniform Commercial Code financing statements filed pursuant to or in connection with any Loan Documents; 
 (d) BWCA does hereby authorize Basin Water to terminate any and all certificates, documents and agreements filed with the U.S. Patent and
Trademark Office or any foreign filing office pursuant to or in connection with any Loan Documents; and 
 (e) BWCA hereby
agrees to, from time to time at the reasonable request and expense of Basin Water, promptly execute and deliver to Basin Water or its designee such further instruments, certificates, documents and agreements, and to file, record or take such further
action reasonably requested by Basin Water to obtain the full benefits of this Amendment and of the rights, remedies and powers herein granted and to effectuate fully the transactions contemplated by and the purposes of this Amendment; provided that
Basin Water will also pay the reasonable expenses, including reasonable attorneys’ fees, of BWCA in connection with its review and delivery to Basin Water of all such instruments and documents (other than this Amendment). In particular, BWCA
shall deliver all Notes (if any) and/or the Loan Agreement to Basin Water (or its designee) in order to mark the same “Cancelled.” Further, BWCA hereby authorizes Basin Water and any of its affiliates to take any other action required to
release the Security Interests created by the Loan Documents. 
 6. Section 16 of each Warrant is hereby deleted in its entirety and
replaced with “Reserved.” 
  

 - 3 - 

 7. All references to Basin Water as a “California corporation” shall be changed to a
“Delaware corporation.” 
 8. Basin Water agrees that BWCA may transfer a portion of each of the Warrants (as amended) in the
amounts and to the parties set forth on Exhibit B hereto. 
 9. Basin Water acknowledges that the shares of Basin Water common stock
issuable upon the cashless exercise of the Warrants will be issued without a restrictive legend and will be fully transferable pursuant to Rule 144(k) under the Securities Act of 1933, as amended, so long as the holder of the shares of Basin Water
common stock is not and has not within three months prior to the sale of any such shares, an “affiliate” of Basin Water, as such term is defined in the rules and regulations of the Securities Act of 1933, as amended. 
 10. This Amendment may be executed in one or more counterparts and with counterpart facsimile signature pages, each of which shall be deemed an original,
but all of which when taken together shall constitute one and the same agreement. 
 11. This Amendment is the product of both of the parties
hereto, and together with the Agreements, constitutes the entire agreement between such parties pertaining to the subject matter hereof, and merges all prior negotiations and drafts of the parties with regard to the matters set forth herein.

 12. This Amendment shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to its
conflicts of law principles. Any proceeding arising out of or relating to this Amendment may be brought in the state or federal courts located in the State of New York. 
 13. All other aspects of the Agreements shall remain unchanged and in full force and effect. From the date hereof, any reference to any of the Agreements shall be deemed to refer to any such Agreement as amended by
this Amendment. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 - 4 - 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first written above. 
  

			
	BASIN WATER, INC.
		
	By:	 	 /s/ THOMAS C. TEKULVE

	Name:	 	Thomas C. Tekulve
	Title:	 	Chief Financial Officer and Treasurer
	
	BWCA I, LLC
		
	By:	 	 /s/ OSCAR TANG

	Name:	 	Oscar Tang
	Title:	 	Authorized Signatory

 Signature Page to Omnibus Amendment 

 EXHIBIT A 
 NOTICE OF EXERCISE 
 To: BASIN WATER, INC. 
 The undersigned hereby elects to purchase                      shares of Common Stock of Basin Water, Inc.,
pursuant to the terms of the attached Warrant. 
 The undersigned hereby elects: 
          to pay the Exercise Price per share required under such Warrant in cash.

          a Cashless Exercise in accordance with the cashless exercise
provisions of Section 4(b)(ii) of the Warrant. 
 So long as the exercise is not a Cashless Exercise, the undersigned hereby represents
and warrants that the representations and warranties contained in Section 10 of the Warrant are true and correct as of the date hereof as if they had been made on such date with respect to the Shares and that the undersigned is acquiring such
shares for its own account for investment purposes only, and not for resale or with a view to distribution of such shares or any part thereof. 
  

			
	HOLDER:
		
	By:	 	  

	[NAME]	 	  

  

			
	Address:	 	  

		 	  

  

			
	Date:	 	  

	
	Name in which shares should be registered:
	  

 EXHIBIT B 
 PERMITTED TRANSFERS 
 (a) With respect to the Warrant to purchase 375,000 shares dated 10/3/2003, the Warrant shall be
reissued in three warrants each for 125,000 to BWCA, and BWCA shall have the right to transfer each warrant in a single transfer after the date hereof. 
 (b) With respect to the Warrant to purchase 177,675 shares dated 10/3/2003, the Warrant shall be reissued in three warrants as follows: (i) one warrant to purchase 10,800 shares in the name of Thomas O’Conner; (ii) one
warrant to purchase 21,675 shares in the name of Douglas Tansill; and (iii) one warrant to purchase 145,200 shares in the name of BWCA. BWCA shall have the right to transfer each warrant in a single transfer after the date hereof. 

(c) With respect to the Warrant to purchase 89,775 shares dated 4/30/2004, the Warrant shall be reissued in two warrants as follows: (i) one warrant to purchase
3,591 shares in the name of Douglas Tansill; and (ii) one warrant to purchase 86,184 shares in the name of BWCA. BWCA shall have the right to transfer each warrant in a single transfer after the date hereof. 
 (d) With respect to the Warrant to purchase 75,000 shares dated 10/26/2004, the Warrant shall be reissued in two warrants as follows: (i) one warrant to purchase
3,000 shares in the name of Douglas Tansill; and (ii) one warrant to purchase 72,000 shares in the name of BWCA. BWCA shall have the right to transfer each warrant in a single transfer after the date hereof. 
 (e) With respect to the Warrant to purchase 50,000 shares dated 2/10/2006, the Warrant shall be reissued in two warrants as follows: (i) one warrant to purchase
2,000 shares in the name of Douglas Tansill; and (ii) one warrant to purchase 48,000 shares in the name of BWCA. BWCA shall have the right to transfer each warrant in a single transfer after the date hereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]